We’re the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity and healing hopelessness with heart. Learn More About Janssen's Phase 3 COVID-19 Vaccine Candidate Study Here. shocks both fans and Alex Trebek: ‘I cannot recall the last time’, Scott Baio, Dean Cain, Kristy Swanson talk Trump and Hollywood in new doc trailer: 'They just don’t like the man', Trump blitzes Pennsylvania, bashes Biden amid push to hold Keystone State, Celebs Who Can't Afford Extravagant Lifestyles, Former Idaho gubernatorial candidate charged in 1984 abduction and killing of Colorado girl, Veritone Licensing Expands Global News Library with Exclusive Agreement with the South China Morning Post, PHOTOS: Justice Ruth Bader Ginsburg — A look back, These Are The Women From Two And A Half Men Now, Ashanti flaunts toned bikini body to celebrate 40th birthday: 'Aging like fine wine', Trump Torched For Mocking Biden, Elderly People With Weird Photoshopped Tweet, Kristen Bell Speaks Out After Husband Dax Shepard's Relapse: 'I Will Continue to Stand by Him', 40 Photos That Prove Prince William Is A Lucky Man, Chaka Khan, 67, says she has bad body image: 'I can't stand in the mirror', GOP sees success in limiting drop boxes in Texas and California, but push to expand them in California, http://www.prnewswire.com/news-releases/johnson--johnson-completes-acquisition-of-momenta-pharmaceuticals-inc-301143938.html. The Ascent is The Motley Fool's new personal finance brand devoted to helping you live a richer life. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 29, 2019, including in the sections captioned 'Cautionary Note Regarding Forward-Looking Statements' and 'Item 1A. We are blending our heart, science and ingenuity to profoundly change the trajectory of health for humanity. Shares of biotechnology company Momenta Pharmaceuticals, Inc. MNTA were up 69.17% after it announced that it will be acquired by pharma giant Johnson & Johnson JNJ for $52.50 per share in an all-cash transaction.The total value of the transaction comes to $6.5 billion.The transaction is expected to close in the second half of 2020. Johnson & Johnson said on Wednesday it would buy Momenta Pharmaceuticals for about $6.5 billion in cash to expand into the area of autoimmune disease treatments. The results demonstrated that nipocalimab induced a rapid and durable response in the myasthenia gravis activities of daily living score (MG-ADL) at all doses and met the study’s primary efficacy endpoint, demonstrating a linear and highly statistically significant (p<0.0001) relationship between Immunoglobulin G (IgG) reduction and MG-ADL clinical benefit. Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. The reader is cautioned not to rely on these forward-looking statements. Joe honed his investing skills as an analyst for Stock Advisor, Supernova, and Fool One. “We’re delighted to welcome Momenta’s talented team to the Janssen Pharmaceutical Companies of Johnson & Johnson and to begin our work together to further advance patient care in autoantibody-driven diseases,” said Jennifer Taubert, Executive Vice President, Worldwide Chairman, Pharmaceuticals, Johnson & Johnson. American Stock Transfer & Trust Company, LLC, the depositary and paying agent for the tender offer, has advised Johnson & Johnson that approximately 100,595,118 shares of Momenta’s common stock were validly tendered and not validly withdrawn in the tender offer, representing approximately 79.4% of the outstanding shares of Momenta’s common stock on a fully diluted basis. The acquisition was completed on October 1, 2020 through a merger of Vigor with and into Momenta in accordance with Section 251(h) of the General Corporation Law of the State of Delaware without a vote of Momenta's stockholders. That's why for more than 130 years, we have aimed to keep people well at every age and every stage of life. In return, J&J would receive full global rights to Momenta's experimental antibody, nipocalimab, which could potentially be used to treat a number of autoimmune diseases. NEW BRUNSWICK, N.J., Oct. 1, 2020 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced it has successfully completed its acquisition of Momenta Pharmaceuticals, Inc. ("Momenta"), a company that discovers and develops novel therapies for immune-mediated diseases, in an all cash transaction for approximately $6.5 billion. We are blending our heart, science and ingenuity to profoundly change the trajectory of health for humanity. These statements are based on current expectations of future events. Are Markets Underpricing Pandemic Impact? We're the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity and healing hopelessness with heart. At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward progress. As a result of the completion of the merger, Momenta’s common stock will be delisted from the NASDAQ Global Select Market. This press release contains 'forward-looking statements' regarding the acquisition of Momenta. 'The Momenta team has made excellent progress in developing its medicines for rare diseases, and we look forward to combining our expertise and resources with theirs to increase that scope,' said Mathai Mammen, M.D., Ph.D., Global Head of Janssen Research & Development, Johnson & Johnson. October 07, 2020 - Johnson & Johnson recently announced the completion of a $6.5 billion pharmaceutical acquisition deal involving biotechnology company Momenta Pharmaceuticals, Inc. . (C) 2020 Electronic News Publishing, source ENP Newswire, Companies Grapple With Sustainability Data -- Journal Report, J&J Hopes Covid-19 Vaccine Trial Will Restart Shortly, Chief Financial Officer & Executive Vice President, Global Chief Information Officer & Executive VP. Momenta’s stock has rallied 164.1% in the year so far compared with the industry’s growth of 2.7%. Follow us at https://twitter.com/JanssenGlobal or www.twitter.com/JanssenUS. J&J executive vice president Jennifer Taubert said the deal would provide the healthcare giant with "a major catalyst for sustained growth" as it enters the autoantibody-driven disease market.

Define Benign, Popular Dress Websites, St Augustine Lighthouse Hours, Pepsico Annual Report 2016, Van Morrison Album Cover Photos, Cats Gross, Peter Pan Return To Neverland Flying Home, Long Sleeve Henley Shirt, Rags Cast Now, Tu Delft Architecture And Urbanism, Realtor Com Deltona, Fl,